Shore Capital reissued their hold rating on shares of AstraZeneca plc (LON:AZN) in a report issued on Wednesday, StockTargetPrices.com reports.
Several other brokerages also recently commented on AZN. Liberum Capital reissued a buy rating and issued a GBX 5,500 ($69.96) price objective on shares of AstraZeneca plc in a research note on Wednesday, June 14th. Credit Suisse Group reissued a neutral rating and issued a GBX 5,000 ($63.60) price objective on shares of AstraZeneca plc in a research note on Monday, June 19th. Jefferies Group LLC increased their price objective on AstraZeneca plc from GBX 5,000 ($63.60) to GBX 5,500 ($69.96) and gave the stock a hold rating in a research note on Friday, June 16th. Deutsche Bank AG reissued a buy rating and issued a GBX 5,700 ($72.50) price objective on shares of AstraZeneca plc in a research note on Monday, June 5th. Finally, Bryan, Garnier & Co reissued a buy rating and issued a GBX 5,400 ($68.68) price objective on shares of AstraZeneca plc in a research note on Tuesday, February 28th. Three investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and nine have issued a buy rating to the company’s stock. The stock presently has a consensus rating of Hold and a consensus target price of GBX 5,251.89 ($66.80).
Shares of AstraZeneca plc (LON AZN) opened at 5429.00 on Wednesday. The company’s market cap is GBX 68.72 billion. The company has a 50 day moving average price of GBX 5,134.14 and a 200 day moving average price of GBX 4,718.55. AstraZeneca plc has a 52 week low of GBX 3,680.00 and a 52 week high of GBX 5,519.00.
TRADEMARK VIOLATION WARNING: This story was posted by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this story on another publication, it was copied illegally and reposted in violation of US and international copyright legislation. The legal version of this story can be read at https://sportsperspectives.com/2017/06/27/astrazeneca-plc-azn-receives-hold-rating-from-shore-capital.html.
About AstraZeneca plc
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.